These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 16100383)

  • 21. [Regulation of autoreactivity by the idiotypic network and therapeutic modulation of autoimmunity by polyvalent intravenous immunoglobulins (IgIV)].
    Lacroix-Desmazes S; Kaveri S; Kazatchkine MD
    Rev Neurol (Paris); 1996 May; 152(5):349-54. PubMed ID: 8881428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
    Shah SR
    Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases.
    Ahmed AR
    Int Immunopharmacol; 2006 Apr; 6(4):557-78. PubMed ID: 16504919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of intravenous immune globulin therapy: an overview.
    Wordell CJ
    DICP; 1991; 25(7-8):805-17. PubMed ID: 1949941
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products.
    Gürcan HM; Keskin DB; Ahmed AR
    Autoimmun Rev; 2010 Jun; 9(8):553-9. PubMed ID: 20346419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety considerations in IGIV utilization.
    Siegel J
    Int Immunopharmacol; 2006 Apr; 6(4):523-7. PubMed ID: 16504914
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Indications and mechanisms of action of the intravenous immunoglobulines in the systemic autoimmune and inflammatory pathologies].
    Mouthon L; Bussone G; Kaveri S
    Rev Med Interne; 2009 Dec; 30(12 Suppl):H14-20. PubMed ID: 19995651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Immunomodulatory effects of intravenous immunoglobulins in autoimmune diseases].
    Mouthon L; Lacroix-Desmazes S; Pashov A; Kaveri SV; Kazatchkine MD
    Rev Med Interne; 1999; 20 Suppl 4():423s-430s. PubMed ID: 10522317
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.
    Orange JS; Hossny EM; Weiler CR; Ballow M; Berger M; Bonilla FA; Buckley R; Chinen J; El-Gamal Y; Mazer BD; Nelson RP; Patel DD; Secord E; Sorensen RU; Wasserman RL; Cunningham-Rundles C;
    J Allergy Clin Immunol; 2006 Apr; 117(4 Suppl):S525-53. PubMed ID: 16580469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous immune globulins. A review of their uses in selected immunodeficiency and autoimmune diseases.
    Pirofsky B; Kinzey DM
    Drugs; 1992 Jan; 43(1):6-14. PubMed ID: 1372861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The new generation of liquid intravenous immunoglobulin formulations in patient care: a comparison of intravenous immunoglobulins.
    Stein MR
    Postgrad Med; 2010 Sep; 122(5):176-84. PubMed ID: 20861601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders.
    Larroche C; Chanseaud Y; Garcia de la Pena-Lefebvre P; Mouthon L
    BioDrugs; 2002; 16(1):47-55. PubMed ID: 11909001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanisms of action of intravenous immunoglobulins.
    Baerenwaldt A; Biburger M; Nimmerjahn F
    Expert Rev Clin Immunol; 2010 May; 6(3):425-34. PubMed ID: 20441428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences between IGIV products: impact on clinical outcome.
    Gelfand EW
    Int Immunopharmacol; 2006 Apr; 6(4):592-9. PubMed ID: 16504921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy.
    Binstadt BA; Geha RS; Bonilla FA
    J Allergy Clin Immunol; 2003 Apr; 111(4):697-703. PubMed ID: 12704346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune globulin IV therapy: optimizing care of patients in the oncology setting.
    Shelton BK; Griffin JM; Goldman FD
    Oncol Nurs Forum; 2006 Sep; 33(5):911-21. PubMed ID: 16955119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of IGIV therapy and infusion-related adverse events.
    Ballow M
    Immunol Res; 2007; 38(1-3):122-32. PubMed ID: 17917017
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of intravenous immunoglobulin therapy in autoimmune and inflammatory disorders.
    Emmi L; Chiarini F
    Neurol Sci; 2002 Apr; 23 Suppl 1():S1-8. PubMed ID: 12032582
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema.
    Jolles S; Hughes J
    Int Immunopharmacol; 2006 Apr; 6(4):579-91. PubMed ID: 16504920
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intravenous immunoglobulin (IVIg) in the treatment of autoimmune and inflammatory diseases.
    Ruiz de Souza V; Kaveri SV; Kazatchkine MD
    Clin Exp Rheumatol; 1993; 11 Suppl 9():S33-6. PubMed ID: 8354005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.